Madrigal Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (13)

Latest Posts

About This Stock More About This Stock
Madrigal Pharmaceuticals: A "Best In Class" Biotech Buy
Article By: MoneyShow.com
Thursday, February 17, 2022 10:23 AM EDT
One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results.
In this article: MDGL
Read
Top Picks For 2022: Madrigal Pharmaceuticals
Article By: MoneyShow.com
Saturday, January 22, 2022 4:15 PM EDT
Madrigal Pharmaceuticals is poised to deliver positive Phase III data in 2022 for resmetirom, its best-in-class NASH (nonalcoholic steatohepatitis) compound.
In this article: MDGL
Read
Madrigal Pharmaceuticals Announces Pricing Of Secondary Offering
Article By: NASDAQ GlobeNewswire
Tuesday, December 10, 2019 10:18 PM EDT
Madrigal Pharmaceuticals, Inc. today announced the pricing of the previously-announced underwritten secondary offering by investment funds affiliated with Bay City Capital LLC, of 1,200,000 shares of Madrigal’s common stock.
In this article: MDGL
Read
Why Madrigal Pharma Boasts 133% Upside
Article By: TipRanks
Monday, November 19, 2018 8:23 AM EDT
Earlier this month, Madrigal announced its Q3 earnings results, and the effect of the earlier stock offerings was clear. The company reported operating expenses of $11.3 million, R&D expenses of $6.2 million, and a $19.2 million cash burn.
In this article: MDGL
Read
5 Hot Stocks For The Second Quarter
Article By: TipRanks
Wednesday, March 28, 2018 9:40 AM EDT
As the Q1 roller-coaster draws to a bumpy close, it’s time to move our attention to the coming quarter.
In this article: MTZ, MU, TGTX, FB, MDGL
Read

Latest Tweets for $MDGL

No tweets yet!

PARTNER HEADLINES